Results 181 to 190 of about 214,376 (295)

The promise of immunotherapy in the treatment of sarcoma: A state-of-the-art review of practice changing research and future directions. [PDF]

Hum Vaccin Immunother
Kulkarni NJ, Kelly CM, Bartlett EK.
europepmc   +1 more source

Engineered Allosteric Biosensor for In Situ DNA Glycosylase Detection in Neuroblastoma Risk Stratification and Drug Resistance Monitoring

Advanced Science, EarlyView.
An engineered allosteric biosensor (UUU‐DZ‐tFNA) was developed, in which UDG specifically recognizes and activates a DNAzyme to achieve signal cycle amplification in a sequentially activatable mode. UUU‐DZ‐tFNA achieves in situ UDG detection across multiple biological levels and facilitates risk stratification and drug resistance monitoring of NB ...
Yaqing Lu, Yingyu Zhang, Xianwei Zhang, Mengxin Zhang, Fei Zhang, Jushan Sun, Yahui Yang, Kangbo Liu, Peng Wang, Shuying Luo, Wancun Zhang   +10 more
wiley   +1 more source

Cryoablation combined with immunotherapy: new strategies and progress in the treatment of tumors. [PDF]

Front Oncol
Xiang Y, Yu L, Li J.
europepmc   +1 more source

Topological Quantum Biomaterials Enable Pyroptosis‐Senescence Coupling for Enhanced Colorectal Cancer Therapy

Advanced Science, EarlyView.
This work reports conceptually unprecedented topological quantum biomaterials derived from engineered Pd3Sn nanostrips for oncological applications. Their near‐Fermi‐level electronic architecture and superior interfacial charge transport facilitate ultrasound‐amplified redox reactions and efficient ROS generation.
Zilu Chen, Kun Mei, Yan Yang, Mengna Xu, Xinyue Dai, Renjun Gu, Fuqiong Zhou, Cheng Wang, Meiqi Chang, Yan Huang, Yu Chen   +10 more
wiley   +1 more source

The promising cancer treatment approach in cancer immunotherapy: dendritic cell-based vaccines. [PDF]

Front Immunol
Wang J, Jia X, Zhang Y, Wang X, Fu Y, He Z.   +5 more
europepmc   +1 more source

CXCL3 Antagonism Reverses Systemic Antitumor Immune Memory Impairment Associated With High Tumor Burden and Sensitizes Anti‐PD‐1 Therapy

Advanced Science, EarlyView.
This study reveals that large tumors secrete more chemokine CXCL3, which recruits immunosuppressive neutrophils to the periphery, thereby impairing the activation and memory of systemic tumor‑reactive CD8+ T cells. CXCL3 antagonism restores systemic immune memory and enhances the antitumor efficacy of anti‑PD‑1 therapy, offering a potential strategy to
Ji Wang, Xinyu Tang, Zeju Li, Qi Qi, Chang Sun, Wen Sun, Weiya Zhang, Yue Yin, Ya Deng, Peiwen Ling, Yifan Xu, Guangshun Sun, Yi Ren, Hong Pan, Shui Wang, Wenbin Zhou   +15 more
wiley   +1 more source

Tumor organoid-immune cell co-culture systems for precision oncology. [PDF]

Front Cell Dev Biol
Cai L, Xiao Y, Xie F, Yang Z.
europepmc   +1 more source

Transformer‐Based Multitask Framework Integrating Habitat and Deep Learning for Predicting Early Disease Control and Survival in Immunotherapy‐Treated Hepatocellular Carcinoma

Advanced Science, EarlyView.
This study developed ECOS‐Net, a transformer‐based multitask framework integrating CT‐derived habitat and 2.5D deep learning features to simultaneously predict early disease control and overall survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors.
Xiaona Fu, Yusheng Guo, Bingxin Gong, Jie Lou, Ning Wang, Xuejun Chen, Hongtao Hu, Rundong Wang, Xiaofang Guo, Shanmei Li, Yangyang Xie, Shichao Long, Mengsi Li, Shubo Pan, Wen Shen, Zhaogang Zhang, Zifang Song, Pengchen Liang, Xiaoyun Liang, Peng Sun, Guilin Zhang, Shanshan Jiang, Jinxiang Zhang, Lian Yang   +23 more
wiley   +1 more source

Oncolytic virotherapy counteracts the selection of IFN-unresponsive cancer cells post-immunotherapy but is limited by the emergence of dedifferentiated cancer cells. [PDF]

Front Immunol
Gellert S, Kruse B, Peters J, Bonifatius S, Tüting T, Buzzai AC.   +5 more
europepmc   +1 more source

Optimizing Cancer Vaccinations Using a Physiologically‐Based Pharmacokinetic/Pharmacodynamic (PBPK/PD) Model

Advanced Science, EarlyView.
Where and when should a cancer vaccine be administered? A whole‐body PBPK model demonstrates that systemic immune transport critically determines vaccination efficacy. By simulating how organ‐specific immune interactions influence treatment response, the study provides a quantitative framework for optimizing cancer vaccination strategies.
Mohammad R. Nikmaneshi, Timothy P. Padera, Lance L. Munn   +2 more
wiley   +1 more source